新辅助纳武利尤单抗联合伊匹木单抗对比化疗治疗可切除非小细胞肺癌
国际III期CheckMate 816试验探索性同期随机队列中,221例可切除NSCLC患者随机接受纳武利尤单抗联合伊匹木单抗(n=113)或化疗(n=108),中位随访49.2个月,联合组中位EFS 54.8个月对比化疗组20.9个月(HR 0.77,95%CI 0.51-1.15),3年OS率73%对61%(HR 0.73,95%CI 0.47-1.14),病理完全缓解率20.4%对4.6%,3-4级治疗相关不良事件发生率14%对36%。
要点
- 纳武利尤单抗联合伊匹木单抗组中位EFS 54.8个月,化疗组20.9个月(HR 0.77,95%CI 0.51-1.15)。
- 联合组3年OS率73%,化疗组61%(HR 0.73,95%CI 0.47-1.14)。
- 联合组病理完全缓解率20.4%,化疗组4.6%;3-4级治疗相关不良事件14%对36%。
核心结论
- 新辅助纳武利尤单抗联合伊匹木单抗对比化疗显示出潜在长期临床获益,尽管术前阶段EFS曲线早期交叉,且高级别毒性发生率更低。
研究设计与样本
- 国际III期CheckMate 816试验的探索性同期随机纳武利尤单抗联合伊匹木单抗与化疗队列。
- 纳入IB-IIIA期(美国癌症联合委员会第七版)可切除非小细胞肺癌成人患者,随机接受3周期纳武利尤单抗每2周一次联合1周期伊匹木单抗,或3周期化疗(每3周周期的第1天或第1天和第8天),随后手术。
- 共221例患者同期随机分配至纳武利尤单抗联合伊匹木单抗组(n=113)或化疗组(n=108)。
- 分析包括无事件生存期、总生存期、病理缓解、手术结局、生物标志物分析和安全性。
主要发现
- 中位随访49.2个月,纳武利尤单抗联合伊匹木单抗组中位EFS为54.8个月(95%CI 24.4至未达到),化疗组为20.9个月(95%CI 14.2至未达到),HR 0.77(95%CI 0.51-1.15)。
- 3年EFS率联合组为56%,化疗组为44%。
- 3年OS率联合组为73%,化疗组为61%,HR 0.73(95%CI 0.47-1.14)。
- 病理完全缓解率联合组为20.4%,化疗组为4.6%。
- 联合组83例(74%)和化疗组82例(76%)接受确定性手术;3-4级治疗相关不良事件发生率分别为14%和36%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Neoadjuvant immune checkpoint blockade with nivolumab plus ipilimumab improves overall survival (OS) in non-small cell lung cancer (NSCLC); however, randomized data for resectable lung cancer are limited. We report results from the exploratory concurrently randomized nivolumab plus ipilimumab and chemotherapy arms of the international phase III CheckMate 816 trial. METHODS: Adults with stage IB-IIIA (American Joint Committee on Cancer seventh edition) resectable NSCLC received three cycles of nivolumab once every 2 weeks plus one cycle of ipilimumab or three cycles of chemotherapy (on day 1 or days 1 and 8 of each 3-week cycle) followed by surgery. Analyses included event-free survival (EFS), OS, pathologic response, surgical outcomes, biomarker analyses, and safety. RESULTS: A total of 221 patients were concurrently randomly assigned to nivolumab plus ipilimumab (n = 113) or chemotherapy (n = 108). At a median follow-up of 49.2 months, the median EFS was 54.8 months (95% CI, 24.4 to not reached [NR]) with nivolumab plus ipilimumab versus 20.9 months (95% CI, 14.2 to NR) with chemotherapy (HR, 0.77 [95% CI, 0.51 to 1.15]); 3-year EFS rates were 56% versus 44%. Higher rates of EFS events were initially seen, with later benefit favoring nivolumab plus ipilimumab; 3-year OS rates were 73% versus 61% (HR, 0.73 [95% CI, 0.47 to 1.14]); pathologic complete response rates were 20.4% versus 4.6%, respectively. In the respective arms, 83 (74%) and 82 patients (76%) underwent definitive surgery. Grade 3-4 treatment-related adverse events occurred in 14% and 36% of patients, respectively. CONCLUSION: Neoadjuvant nivolumab plus ipilimumab showed potential long-term clinical benefit versus chemotherapy, despite early crossing of EFS curves in the preoperative phase and a lower rate of high-grade toxicity.
引用
- Awad MM, Forde PM, Girard N, et al. Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer. J Clin Oncol. 2025. PMID: 39778121. doi:10.1200/JCO-24-02239
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。